ProText Mobility Chairman Reports 831.3 Million TXTM Common Shares; Management Reaffirms No Preferred ConversionsMCAP MediaWire · Oct 13, 2026
ProText Mobility Chairman Confirms 831.3 Million Common Shares in SEC Filing — Chairman and CEO Reaffirm Zero Preferred Conversions, Unified Management Philosophy and Shareholder SolidarityGlobeNewsWire · Oct 13, 2026
ProText Mobility Issues Significant Inter-Quarter Shareholder Update: ABSA Confirms Inaugural Digital-Asset Custody Pilot as TXTM Advances Global RWA and Uplist StrategyGlobeNewsWire · Sep 28, 2026ProText Mobility, Inc., a biotech company, engages in the development of pharmaceutical botanical medicines. Its medicines are formulated with highly-bioavailable plant extracts. The company is based in Fort Lauderdale, Florida.